Oxford BioDynamics FY26 H1 operating loss narrows to £4.68 million; revenue rises to £0.69 million

  • Oxford BioDynamics posted revenue of £687,000, up 17% from the year-earlier period, in interim results for the six months ended March 31, 2026.
  • Operating loss narrowed to £4.68 million from £5.88 million; loss per share improved to 0.1p from 0.7p.
  • PSE test orders rose 66% versus H2 2025 to 1,788, with sales growth particularly in the US.
  • Cash and cash equivalents totaled £2.51 million at March 31, 2026; cash at May 31 was £1.38 million with additional funding needed by late August 2026.
  • Richard Compton was appointed CEO; EpiSwitch Orion launched in March 2026, with commercial talks under way with three large pharma companies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oxford Biodynamics plc published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.